JAMA Internal Medicine : Decision Aids for Prostate Cancer Screening Choice
Interview with Kari A O Tikkinen, MD, PhD, author of Decision Aids for Prostate Cancer Screening Choice: A Systematic Review and Meta-analysis
Conclusions There was variable uptake of the PtDAs between the cases. Men who received the PtDA had positive outcomes. Several strategies were identified to increase or sustain PtDA use. Implications for Practice Nurses have a key role in supporting men making decisions about prostate cancer treatment by providing PtDAs, answering questions, and advocating for men's preferences.
Researchers are touting the efficacy of a new, incision-free MRI-guided procedure...Read more on AuntMinnie.comRelated Reading: MRI restaging for recurrent prostate cancer has its flaws Prostate cancer patients prefer mpMRI over biopsy Which biopsy method best detects prostate cancer? AIUM: TRUS or MRI for prostate diagnosis? Multiparametric MRI aids in prostate cancer follow-up
CONCLUSIONS: Urinary PCA3 has an acceptable diagnostic accuracy, aids in the study of patients with suspected prostate cancer, and can be used as a guide for directing the performance of the first prostate biopsy and decreasing unnecessary biopsies. PMID: 31793864 [PubMed - as supplied by publisher]
(Medical College of Georgia at Augusta University) A transcription factor that aids neuron function also appears to enable a cell conversion in the prostate gland that can make an already recurrent cancer even more deadly, scientists say.
Sepsis is a healthcare condition with âincredible unmet need,â Ajay Shah, cofounder and CEO of Cytovale, tells MD+DI. âMore people die from sepsis than from breast cancer, prostate cancer, and AIDS combined each year, and it costs more than $20 billion a year to treat sepsis in the United States.â Complicating matters is that sepsis âis challenging to diagnose early in the emergency department,â he added. Cytovale is hoping to tackle sepsis through early diagnosis. The company is developing a diagnostic test that cou...
Publication date: Available online 31 October 2019Source: International Journal of PharmaceuticsAuthor(s): Mohammadjavad Jahanshahi, Elaheh Kowsari, Vahid Haddadi-Asl, Mehdi Khoobi, Jong Hyun Lee, Firoz Babu Kadumudi, Sepehr Talebian, Nazila Kamaly, Mehdi MehraliAbstractFluorinated graphene has recently gained much attention for cancer drug delivery, owing to its peculiar properties including high electronegativity difference, magnetic resonance imaging contrast agent, and the photothermal effect. However, the hydrophobic nature of fluorinated graphene greatly hinders its application as a biological material. Herein, a nov...
When it comes to prostate cancer screening, decision aids cannot replace a conversation between a man and his physician.Medscape Urology
How clinically effective is MRI-guided biopsy for prostate cancer? The modality...Read more on AuntMinnie.comRelated Reading: Which biopsy method best detects prostate cancer? AIUM: TRUS or MRI for prostate diagnosis? MRI-guided cryoablation a boon for HCC patients Multiparametric MRI aids in prostate cancer follow-up Societies eye role for prostate MRI-guided biopsy
Patient decision aids (PDAs) can support the treatment decision making process and empower patients to take a proactive role in their treatment pathway while using a shared decision-making (SDM) approach makin...